This content is from: Premium
Averill Launches a New Fund
Averill Madison will have a long bias and will focus primarily on large-cap stocks.
Biopharma specialist Averill Partners has launched Averill Madison, a new offshoot fund, according to an investor. The new fund, which began trading in November, currently has $130 million under management. However, according to the investor, Madison is thought to be more scalable than the
To continue reading, subscribe now to Premium Journalism. Already a subscriber? Login.